Thyroid gland squamous cell carcinoma
MONDO:0006467A rapidly growing primary carcinoma of the thyroid gland composed of malignant squamous cells. The clinical course is usually aggressive.
Also known as: squamous cell thyroid gland carcinoma, thyroid gland squamous cell carcinoma
2750 clinical trials for this condition and its sub-types, 4 tagged with Thyroid gland squamous cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug cocktail shows promise against deadly thyroid cancer before surgery
Disease control OngoingThis study tests whether giving three drugs (pembrolizumab, dabrafenib, and trametinib) before surgery can help people with a rare and aggressive thyroid cancer called anaplastic thyroid cancer that has a specific gene change (BRAF V600E). The goal is to shrink the tumor enough s…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for rare, aggressive thyroid cancer: drug combo shows promise
Disease control OngoingThis phase 2 trial tests whether combining lenvatinib (a targeted drug that blocks cancer growth) with pembrolizumab (an immunotherapy that helps the immune system attack cancer) can improve outcomes for people with advanced anaplastic thyroid cancer that cannot be surgically rem…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control OngoingThis phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Targeted drug before surgery shows promise for RET-Altered thyroid cancer
Disease control OngoingThis phase 2 trial tests whether giving selpercatinib before standard surgery can shrink tumors in people with RET-altered thyroid cancer. About 30 participants with advanced or recurrent disease will receive the drug and then undergo surgery. The goal is to see if the drug impro…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC